Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-04
2010-02-16
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252130, C514S253090, C514S253130, C514S254050, C514S255020, C514S218000, C514S326000, C514S327000, C514S422000, C514S424000, C540S575000, C544S121000, C544S357000, C544S365000, C544S369000, C544S370000, C544S372000, C544S383000, C544S384000, C544S129000, C544S130000, C546S187000, C546S208000, C546S221000, C546S234000, C548S518000, C548S550000, C548S556000
Reexamination Certificate
active
07662816
ABSTRACT:
Disclosed are compounds of the formulaor a pharmaceutically acceptable salt or solvate thereof, whereinR1isR is —C(O)—N(R27)(R28) orand the remaining variables are as defined in the specification.Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
REFERENCES:
patent: 6683091 (2004-01-01), Asberom et al.
patent: WO 95/18104 (1995-06-01), None
patent: WO 0007995 (2000-02-01), None
patent: WO 0050391 (2000-08-01), None
patent: WO 0202505 (2002-01-01), None
patent: WO 0202506 (2002-01-01), None
patent: WO 0202512 (2002-01-01), None
patent: WO 0202518 (2002-01-01), None
patent: WO 0202520 (2002-01-01), None
patent: WO 02/002520 (2002-10-01), None
patent: WO 02088101 (2002-11-01), None
patent: WO 03013527 (2003-02-01), None
patent: WO 03018543 (2003-03-01), None
patent: WO 03066592 (2003-08-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (2001).
Hom, Expert Opin. Ther. Patents, vol. 17,p. 737-740 (2007).
English translation for WO 95/18104 (Jun. 7, 1995).
McGaughey et al. Expert Opin.Drug Discov. vol. 2 (8),pp. 1129-1138 (2007).
Melnikova, Nature Reviews Drug Discovery, vol. 6, p. 341-342 (2007).
Philip L. Gould, Salt Selection for Basic Drugs,International Journal of Pharmaceutics, 33(1986) 201-217.
George R. Pettit, et al., The Dolastatins; 18: Stereospecific Synthesis of Dolaproine,Synthesis, (1996) 719-725.
Ugo Pfeiffer, et al., A Short Synthesis of 4-Imidazolidinone,Liebigs Ann. Chem., (1988) 993-995.
Bruno Bellier, et al., Synthesis and Biological Properties of New Constrained CCK-B Antagonists: Discrimination of Two Affinity States of the CCK-B Receptor on Transfected CHO Cells,J. Med. Chem., (1997) 40:3947-3956.
Thomas R. Webb, et al., Conformationally Restricted Arginine Analogues,J. Org. Chem., (1991) 56:3009-3016.
Stephen Hanessian, et al., The Power of Visual Imagery in Synthesis Planning. Stereocontrolled Approaches to CGP-60536B, a Potent Renin Inhibitor,J. Org. Chem., (2002) 67:4261-4274.
Samuel Chackalamannil, et al., Total Synthesis of (+)-Himbacine and (+)-Himbeline,J. Org. Chem. (1999) 64:1932-1940.
Christoph Hock, et al., Generation of Antibodies Specific for β-amyloidby Vaccination of Patients with Alzheimer Disease,Nature Medicine, (2002) 8:1270-1275.
Toshimasa Itoh et al., Asymmetric Synthesis of (−)-Adaline,Organic Letters, (2002) 4:2469-2472.
Christopher J. Dinsmore, et al., 3,8-Diazabicyclo[3.2.1]octan-2-one Peptide Mimetics: Synthesis of a Conformationally Restricted Inhibitor of Farnesyltransferase,Organic Letters, (2001) 3:865-868.
Lawrence I. Kruse, et al., Multisubstrate Inhibitors of Dopamine β-Hydroxylase. 2.1Structure-Activity Relationships at the Phenethylamine Binding Site,J. Med. Chem., (1987) 30:486-494.
Zhenping Tian et al., An Efficient Scalable Process for the Synthesis of N-Boc-2-tert-butyldimethylsiloxypyrrole,Organic Process Research&Development, (2002) 6:416-418.
Gordon Lowe et al., Amino Acid Bearing Nucleobases for the Synthesis of Novel Peptide Nucleic Acids,J. Chem. Soc., Perkin Trans. 1, (1997) 539-546.
Stephen M. Berge, et al., Pharmaceutical Salts,Journal of Pharmaceutical Sciences(1977) 66:1-19.
International Search Report for International Application No. PCT/US2004/025018, mailed Aug. 22, 2005, (5 pages).
Babu Suresh D.
Chackalamannil Samuel
Cumming Jared N.
Guo Tao
Hobbs Douglas W.
Bernhardt Emily
Lee William
MacMillan Keith D.
Magatti Anita
Schering Corporation
LandOfFree
Cyclic amine BACE-1 inhibitors having a benzamide substituent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amine BACE-1 inhibitors having a benzamide substituent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amine BACE-1 inhibitors having a benzamide substituent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158575